• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

Antibody-drug Conjugate/ADC Related

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

 

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Products of the following targets

Products of the following indications

Tags: buy Antibody-drug Conjugate/ADC Related materials | Antibody-drug Conjugate/ADC Related ic50 | Antibody-drug Conjugate/ADC Related price | Antibody-drug Conjugate/ADC Related cost | Antibody-drug Conjugate/ADC Related inhibitor dmso | Antibody-drug Conjugate/ADC Related purchase | Antibody-drug Conjugate/ADC Related inhibitors manufacturer | Antibody-drug Conjugate/ADC Related research buy | Antibody-drug Conjugate/ADC Related order | Antibody-drug Conjugate/ADC Related mouse | Antibody-drug Conjugate/ADC Related chemical structure | Antibody-drug Conjugate/ADC Related pharmaceuticals | Antibody-drug Conjugate/ADC Related weight | Antibody-drug Conjugate/ADC Related active molecules | Antibody-drug Conjugate/ADC Related APIs supplier | Antibody-drug Conjugate/ADC Related in vitro | Antibody-drug Conjugate/ADC Related cell line | Antibody-drug Conjugate/ADC Related concentration | Antibody-drug Conjugate/ADC Related signaling pathway